Oxotremorine sesquifumarate
CAS : 17360-35-9
Ref. 3D-SAA36035
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté |
Informations sur le produit
- 1-(4-pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one (2E)-but-2-enedioate
- 1-(4-pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one (2E)-but-2-enedioate (2:3)
- 1-[4-(2-Oxopyrrolidin-1-Yl)But-2-Yn-1-Yl]Pyrrolidinium
- 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butyn-1-yl]-, (2E)-2-butenedioate (2:3)
- 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-, (2E)-2-butenedioate (2:3)
- 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-, (E)-2-butenedioate (2:3)
- 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-, fumarate (2:3)
- Oxotremorine fumarate (2:3)
- Oxotremorine sesquifumarate salt
Oxotremorine sesquifumarate is a cholinergic drug that is used as an allosteric modulator of the nicotinic acetylcholine receptor. It produces its effects by binding to the M2 muscarinic acetylcholine receptor and blocking the binding of acetylcholine. Oxotremorine sesquifumarate has been shown to have an inhibitory effect on serotonin reuptake, which may be due to its ability to competitively bind with serotonin receptors in the brain. This drug also has a depressant effect on locomotor activity and bladder function, but does not affect blood pressure or maleate levels in mice.